ASH Attendees Question Ethics, Results Of Major CLL Trials
Trials of Roche’s Gazyva and Gilead’s idelalisib draw scrutiny as ASH attendees express concern about whether comparators were good enough. Investigator on Roche/AbbVie’s Bcl-2 inhibitor GDC-0199/ABT-199 study gets flak for lack of oversight that resulted in death.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.